Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Resources, news and special offers to support you and your professional development during this difficult time.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Download your copy of the new events calendar and see all the online workshops, conferences, RAC exams and European online workshops RAPS has planned for 2021 at a glance.
Registration is now open for RAPS Euro Convergence 2021! Attend to join peers from EU and around the world to gain insights and exchange ideas on the regions most pressing issues.
An invaluable resource for any professional engaged in designing, composing, compiling, or commenting on regulatory documentation
From self-assessments to help you identify your strengths and areas to focus on to reference books and online courses that will help you fill in the gaps in your regulatory knowledge, RAPS has the resources to help you prepare for the RAC exam.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
Posted 21 May 2014 | By Alexander Gaffney, RAC,
US Food and Drug Administration (FDA) regulators are proposing to reclassify some Influenza Antigen Detection Test Systems into a higher-risk category than the systems now inhabit, citing potential for the devices to fail to detect newer versions of the virus.
The devices, which are used to detect the presence of influenza in a clinical sample, were Classified as low-risk Class I medical devices in 1982. Class I devices only require the company to adhere to general controls and do not require a premarket submission such as a 510(k) or premarket application.
As FDA explains, in 1982, "Influenza tests conceived to fall under this regulation were laboratory methods to detect antibodies that develop in response to influenza infection while the detection of the influenza virus itself was done primarily by viral culture. As enzyme immunoassay technology developed, tests capable of detecting viral proteins (antigens) directly in human respiratory samples began to come to FDA for clearance."
Since then, FDA notes that "methods utilizing antigens and antibodies as components of an influenza detection device" have been approved or cleared for use, and that 12 of those tests remain on the market today.
And while those devices are easier to use and provide the user with faster results than older influenza detection tests, they have been known to fail. FDA pointed to the 2009 flu pandemic, which was notable for the poor performance of Rapid Influenza Detection Tests (RIDTs). Misdiagnoses were common, and potentially resulted in serious and even fatal consequences for patients.
"Failure of the device to perform as indicated (producing erroneous or inaccurate results) could mislead the physician and cause inappropriate or delayed medical treatment of a patient," FDA wrote. "Failure of the test to produce accurate test results can also lead to inaccurate epidemiological information that may contribute to inappropriate public health responses and to facilitate spread of the infection in a community."
One of FDA's advisory panels recommended in 2013 that the device be reclassified as a Class II device to better reflect the special controls needed to ensure that devices are capable of detecting changes in the virus as it mutates over time.
FDA has now formally agreed with that assessment, and in a proposed rule published on 21 May 2014 has proposed classifying the devices as Class II, requiring the submission of a 510(k) application and subjecting the devices to special controls.
Those controls include requirements to meet at least one clinical performance criteria established by FDA, to perform annual testing with contemporary strains of the virus, and keep labeling up to date with current influenza emergency findings by FDA and other health agencies.
Federal Register Announcement
Tags: CDRH, Flu, Influenza, RIDT, Class II, Special Controls, Reclassification, Re-Classification
Regulatory Focus newsletters
All the biggest regulatory news and happenings.